Evonik Industries | EDQM | Inspections & Registrations

Corporate Presentation

GMP Certificate 2024

Rexiva®

Lipid-based Delivery of Nucleic Acids

PhytoSquene®

Nutraceutical Solutions

Evonik Strengthens its Animal Nutrition Business

New U.S Facility for Pharmaceutical Lipids

Production Capacity for DL-Methionine in Singapore

Evonik invests $220M with US Govt. for lipid production facility

Specialty Additives Division Spotlight

cQrex™ Cell Culture Solutions

Complex Parenterals

Exclusive Synthesis

Oral Drug Delivery Solutions

Resomer®

Nutrition & Care Divison Spotlight

Smart Materials Division Spotlight

Eudragit®

PhytoChol®

Custom Lipids

Evonik Birmingham Laboratories

High-quality Generic APIs, Intermediates & Amino Acids

Your Enabling Partner for Oral Drug Delivery Solutions

Click the button for full data set

AMINOSys®

Applied Technology Center

Catalysts - Adsorbent Solutions

Custom Catalysts

Interface & Performance Laboratory

TEGO® Foamex 8880

Lipid Innovation Center

cQrex® AC

Discover Our New Oral Drug Delivery Lab in Istanbul

CDMO for Advanced Drug Delivery

EUDRATEC® SoluFlow

Drawing Drug Delivery: Liposomes

Coatino®

Evonik Delivers First Lipids from German Facility to BioNTech

Hydrogen Peroxide

Polyamide 12

SEPURAN® Green

Specialty Additives

DATA COMPILATION #PharmaFlow

Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination

The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards. Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio. Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients. The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience. View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.

Impressions: 773

CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik.View CDMO Activity Tracker for H1 2024 (Free Excel Available) Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services.View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs.View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal.View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines.

Impressions: 2458

NEWS #PharmaBuzz

Evonik Starts New Spray Drying Facility For Pharma Oral Excipients

11 Sep 2024

// INDIANPHARMAPOST

Evonik completes sale of superabsorbents business to ICIG

02 Sep 2024

// REUTERS

Evonik expands its formulation capabilities for lipid nanoparticles

16 Aug 2024

// INDIANPHARMAPOST

PhytoSquene® Assessed: Your plant-powered vaccine adjuvant

29 Jul 2024

// FIERCE PHARMA

Evonik appoints Yann d’Hervé as new head of Health Care business line

01 Jul 2024

// PRESS RELEASE

Evonik presents nutraceutical innovations at Vitafoods Europe 2024

14 May 2024

// PRESS RELEASE

ALL APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

01

Azelastine Hydrochloride

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 15440

Submission : 2001-05-15

Status : Active

Type : II

02

Chlorhexidine Base

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 5926

Submission : 1985-07-02

Status : Active

Type : II

03

Chlorhexidine Digluconate

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 8379

Submission : 1990-01-19

Status : Active

Type : II

04

Glycine

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : Complete

Rev. Date : 2017-03-31

Pay. Date : 2016-12-27

DMF Number : 30393

Submission : 2016-03-02

Status : Active

Type : II

05

L - Serine

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37552

Submission : 2022-10-13

Status : Active

Type : II

06

L-alanine

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 19769

Submission : 2006-08-28

Status : Active

Type : II

07

L-alanyl-l-glutamine

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 9486

Submission : 1992-01-03

Status : Active

Type : II

08

L-aspartic Acid

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 19766

Submission : 2006-08-28

Status : Active

Type : II

09

L-lysine Hydrate

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 3872

Submission : 1980-07-11

Status : Active

Type : II

10

L-methionine

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Evonik

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 18726

Submission : 2005-08-31

Status : Active

Type : II

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

Only 10 entries up to this point, click to access all

VMF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

LISTED APIs

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

01 Evonik

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : Cellulose

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : JeNaCell

Deal Size : Not Applicable

Deal Type : Not Applicable

Evonik Company JenaCell Launches Wound Dressing Epicite® Balance for Chronic Wounds

Details : epicite® balance is made of biosynthetic cellulose, a hydropolymer for innovative medical device applications. The dressing enables superior wound cleansing effects and reactivates the healing of slow-healing ...

Brand Name : Epicite® Balance

Molecule Type : Large molecule

Upfront Cash : Not Applicable

July 14, 2023

02 Evonik

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : Cellulose

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : JeNaCell

Deal Size : Not Applicable

Deal Type : Not Applicable

Evonik Company JeNaCell Launches Wound Dressing Epicite® Balance for Chronic Wounds

Brand Name : Epicite® Balance

Molecule Type : Large molecule

Upfront Cash : Not Applicable

June 13, 2023

03 Evonik

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : Bupivacaine

Therapeutic Area : Neurology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Allay Therapeutics

Deal Size : Not Applicable

Deal Type : Not Applicable

No Opioids After Surgery: Evonik Invests in Allay Therapeutics and Supplies Key Technology for Pai...

Details : ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.

Brand Name : ATX-101

Molecule Type : Small molecule

Upfront Cash : Not Applicable

December 13, 2022

04 Evonik

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : Phathom Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Agreement

Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan

Details : Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.

Brand Name : Voquezna Triple Pack

Molecule Type : Small molecule

Upfront Cash : Undisclosed

October 24, 2022

05 Evonik

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : mRNA-based Therapy

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Undisclosed

Partner/Sponsor/Collaborator : BARDA

Deal Size : $220.0 million

Deal Type : Funding

Evonik Invests US$220 Million in Partnership with The U.S. Government to Build New Lipid Productio...

Details : Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects t...

Brand Name : Undisclosed

Molecule Type : Large molecule

Upfront Cash : Undisclosed

June 02, 2022

06 Evonik

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : Simufilam

Therapeutic Area : Neurology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Cassava Sciences

Deal Size : Undisclosed

Deal Type : Agreement

Evonik and Cassava Sciences Join Forces to Fight Alzheimer’s Disease

Details : Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation a...

Brand Name : PTI-125

Molecule Type : Small molecule

Upfront Cash : Undisclosed

March 09, 2021

07 Evonik

Germany

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Lead Product(s) : Tozinameran

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved

Partner/Sponsor/Collaborator : BioNTech

Deal Size : Undisclosed

Deal Type : Partnership

Evonik Strengthens Strategic Partnership with Biontech on Covid-19 Vaccine

Details : Lipids are fundamental to produce highly effective mRNA-based vaccines. Only with an increase in lipid supply can the volume of vaccine be further increased. This move marks an expansion of the partnership betw...

Brand Name : Comirnaty

Molecule Type : Vaccine

Upfront Cash : Undisclosed

February 11, 2021

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Services

Discover the service capabilities from this company

API Manufacturing

Discover their expertise for :

Scale Up

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Clinical Supply

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Small Molecules

01

CONTRACT MANUFACTURING OF SMALL ...

Germany

For more than 20 years, Evonik has served as a preferred global contract manufacturing partner to commercialize small molecule APIs, advanced intermediates, biopharmaceutical or fermentation based products.

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Pharma Service : API Manufacturing

Evonik

Category : Small Molecules

Sub Category : Overview

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Pharma Service : API Manufacturing

CONTRACT MANUFACTURING OF SMALL MOLECULE APIs

Service
Web Link

Capabilities
#ServicesBio

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Chiral Synthesis

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GMP Manufacturing

01

API GMP MANUFACTURING

Germany

Evonik's sites across Europe, the US and Asia are equipped with some of the most advanced facilities in the CMO industry for the GMP manufacturing of active pharmaceutical ingredients (APIs) utilizing either batch or continuous processes.

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Pharma Service : API Manufacturing

Evonik

Category : GMP Manufacturing

Sub Category : Overview

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Pharma Service : API Manufacturing

API GMP MANUFACTURING

Service
Web Link

Capabilities
#ServicesBio

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Small Scale Batch

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Controlled Substance

01

CMO FOR CONTROLLED SUBSTANCES

Germany

Evonik has the world’s largest and most versatile capacity for the commercial-scale manufacturing of controlled APIs. It has multi-purpose cGMP site with 180 m³ capacity for producing controlled substances from a few grams to thousands of tons per year.

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Pharma Service : API Manufacturing

Evonik

Category : Controlled Substance

Sub Category : Overview

Evonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Pharma Service : API Manufacturing

CMO FOR CONTROLLED SUBSTANCES

Service
Web Link

Capabilities
#ServicesBio